Flaxseed Oil Human Clinical Research: What the Evidence Shows

Executive Summary of Flaxseed Oil Human Evidence

Laboratory and animal studies on alpha-linolenic acid (ALA) are plentiful, but the question most readers ask is simpler: does taking the oil change measurable health outcomes in people? Flaxseed oil human clinical research gives a more modest answer than marketing suggests. Trials exist, but they are mostly small, short and focused on surrogate markers rather than disease events.

What the human studies examined. The outcomes with the most data are blood lipids, blood pressure, inflammatory markers and skin barrier measures. Individual trials have also looked at markers of lipid oxidation.

What looks promising, inconclusive or unsupported:

• Blood lipids: a meta-analysis of randomized trials found lipid reductions with whole flaxseed and lignan supplements but not with flaxseed oil (Pan et al., 2009). A later analysis reached a similar conclusion for lipids in patients with dyslipidemia-related diseases.
• Blood pressure: pooled analyses of flaxseed products show small average reductions. Oil-specific evidence is thin, with wide confidence intervals.
• Inflammation: results conflict. A crossover trial in healthy young adults found no difference from olive oil, while a pooled analysis in patient populations reported lower IL-6 and hs-CRP.
• Skin: one small randomized trial reported improved barrier measures. It has not been replicated here.
• Clinical events: none of the sources reviewed demonstrate that flaxseed oil prevents heart attack, stroke, diabetes or death.

Oil versus seed. Flaxseed oil is only the extracted fat fraction. Whole and ground flaxseed also supply fiber and lignans, which may explain why seed-based results do not carry over to the oil. See the identity page in this cluster for definitions.

Overall strength of evidence: low to very low for every outcome reviewed, as shown below.

Research Question for Flaxseed Oil Human Clinical Research

The principal question is: in humans, does supplementation with flaxseed oil, compared with placebo, another oil or usual diet, change clinically relevant outcomes?

Formulation matters because "flaxseed" is not one intervention. Whole seed delivers fiber and lignans alongside ALA. The oil delivers mainly ALA, with oleic and linoleic acid. Isolated ALA and lignan extracts are different again. Pooling these products can hide the fact that an effect belongs to one component. Where a source mixes products, this article says so.

Search and Inclusion Methodology

This is a narrative evidence review, not a systematic review. It did not follow a registered protocol, dual screening or a full PRISMA workflow, and a reproducible database search was not completed.

• Sources searched: web searches surfacing PubMed-indexed abstracts, publisher and open-access pages (PubMed Central), and ClinicalTrials.gov records.
• Search terms used: "flaxseed oil randomized controlled trial meta-analysis blood lipids"; "flaxseed oil inflammatory markers olive oil"; "flaxseed oil blood pressure meta-analysis"; and "flaxseed oil skin barrier".
• Date of most recent search: 13 October 2026.
• Inclusion: human studies in which flaxseed oil was the intervention, plus meta-analyses that reported flaxseed oil results or subgroups.
• Exclusion: animal and cell studies, and studies where flaxseed oil was bundled with other active ingredients.
• Priority: systematic reviews and meta-analyses, then randomized trials, then observational data.
• Duplicates and mixed interventions: each study is counted once. Mixed-product meta-analyses are reported with their caveats, not attributed to the oil alone.
• Missing data: where full texts were not accessible, details such as sample size, funding or exact dose are marked as not extracted rather than estimated.

Because coverage is limited, relevant trials will be missing. Treat the tables as a verified sample, not a complete census.

Flaxseed Oil Health Outcomes in Human Studies

Blood lipids

Pan and colleagues pooled 28 randomized trials of flaxseed or its derivatives. Overall, flaxseed lowered total cholesterol by 0.10 mmol/L (95% CI -0.20 to 0.00) and LDL cholesterol by 0.08 mmol/L (95% CI -0.16 to 0.00). Reductions were significant for whole flaxseed and lignan supplements but not for flaxseed oil (Pan et al., 2009). A 2021 dose-response meta-analysis in patients with dyslipidemia-related diseases likewise found that the oil did not lower lipids (Nutr Metab, 2021). A 2026 dose-response meta-analysis of flaxseed oil and lipids has also appeared, but its results could not be fully extracted for this review.

Blood pressure

Pooled analyses of mixed flaxseed products report small reductions. Khalesi and colleagues found about 1.8 mmHg lower systolic and 1.6 mmHg lower diastolic pressure, with larger effects for whole seed and longer duration (Khalesi et al., 2015). The analysis most specific to the oil included five trials (six arms) in patients with metabolic syndrome and related disorders and reported a systolic reduction of 3.86 mmHg (95% CI -7.59 to -0.13) (Mahmudiono et al., 2022). The confidence interval nearly reaches zero, so the result is fragile.

Inflammatory markers

Results diverge by population. In a randomized crossover trial of healthy, normal-weight young adults, 15 mL/day of flaxseed oil for six weeks did not differ from olive oil for adiponectin, TNF-alpha, hs-CRP, glucose or lipids (Kontogianni et al., 2013). In patients with dyslipidemia-related diseases, a pooled analysis found the oil lowered IL-6 (-0.35 pg/mL, P = 0.033) and hs-CRP (-1.54 mg/L, P = 0.004) (Nutr Metab, 2021). The pattern suggests any effect may depend on baseline inflammation and background diet, but that remains a hypothesis.

Skin outcomes

A 12-week double-blind trial in women with sensitive skin compared flaxseed oil with safflower oil. The flaxseed oil group showed less sensitivity after nicotinate irritation, lower transepidermal water loss, less roughness and scaling, and higher hydration (Neukam et al., 2011). With 13 women per group, this is preliminary.

Oxidation markers and other outcomes

In healthy men taking 9 g/day for four weeks, flaxseed oil raised plasma ALA and F1-phytoprostanes (oxidation products of ALA) compared with olive oil, while F2-isoprostanes, a marker of whole-body lipid peroxidation, did not change. Glycemic outcomes, bone, cognitive and eye outcomes were not supported by verified oil-specific trials in this review, so none are claimed.

Surrogate markers are not disease outcomes

A 2 mmHg drop in blood pressure or a small change in hs-CRP is a laboratory or physiological measurement. It does not establish fewer cardiovascular events. No flaxseed oil trial reviewed here was designed or powered for such events.

Table of Flaxseed Oil Clinical Studies

Only studies verified through abstracts or registry records are listed. "Not extracted" means the detail was not available in the sources accessed.

Study Design Quality

Randomization, concealment and blinding are not equally well reported across the sources. Oils differ in taste and smell, so blinding is hard, and some designs compared flaxseed oil with another oil rather than an inert placebo. That matters because an active comparator can mask or create a difference. Olive oil, for example, has its own cardiometabolic effects.

Sample sizes are small. The skin trial enrolled 13 women per group, too few for stable estimates or subgroup analysis. Attrition, adherence checks and missing data are rarely described in abstracts. Adherence was checked objectively in at least one trial, by measuring fatty acids in red blood cells (Kontogianni et al., 2013), which is good practice.

Preregistration is uneven. A registry record exists for at least one trial (NCT00967733), but whether published trials reported every prespecified outcome could not be confirmed here. Selective outcome reporting therefore remains a risk. Overall, the risk of bias ranges from some concerns to high, which limits confidence in any single result.

Participant Characteristics

Participants cover a narrow range. Individual trials enrolled healthy young adults, healthy men and women with sensitive skin. Meta-analyses add patients with metabolic syndrome or dyslipidemia-related diseases. Pan and colleagues concluded that lipid effects of flaxseed depended on intervention type, sex and starting lipid levels.

This affects generalizability. A null result in healthy, normal-weight adults eating an olive-oil-rich diet says little about people with raised cholesterol or inflammation. Underrepresented groups include older adults, children, pregnant and breastfeeding women, people with kidney disease and people from varied dietary backgrounds.

Dose and Form Used

Doses are reported as grams or milliliters of oil, not always as ALA. Flaxseed oil is typically about half ALA by weight, so ALA doses below are rough estimates, not reported values.

These doses are not interchangeable with fish oil, EPA, DHA, whole flaxseed or lignan extracts. The body converts only a small share of ALA to EPA and DHA (Burdge and Calder, 2005), so ALA doses cannot be read as marine omega-3 doses. The cluster's dosage page covers serving guidance.

Duration

Trials ran from four weeks (oxidation markers) to six weeks per arm (inflammation, crossover) and 12 weeks (skin). Meta-analyses suggest blood pressure effects may be larger after more than 12 weeks (Khalesi et al., 2015), so a six-week trial may be too short to see them. Lipid and inflammatory markers can shift within weeks, but whether any change persists is unknown.

No verified trial followed participants for years. Long-term safety and long-term effects on clinical outcomes therefore remain unstudied for the oil specifically.

Primary Endpoints

• Kontogianni et al.: inflammatory and biochemical markers (adiponectin, TNF-alpha, hs-CRP, glucose, lipids). These are surrogate markers.
• Neukam et al.: skin sensitivity, TEWL, hydration, roughness and scaling. These are physiological and appearance measures, not diagnoses.
• Barden et al.: oxidation biomarkers, relevant to safety questions about oxidizing a fragile fatty acid.
• Meta-analyses: lipids, systolic and diastolic blood pressure, IL-6 and hs-CRP.

None of these is a clinical outcome such as cardiovascular events or disease progression. Separating primary from secondary endpoints is often impossible from abstracts alone, so findings should be read as hypothesis-generating unless a trial prespecified them.

Results

The numbers below are the authors' reported results. Interpretation follows in the next section.

Several of these confidence intervals approach zero. A statistically significant result is not automatically a clinically important one.